A phase I trial of OCR-002 for prevention of hepatic encephalopathy in healthy volunteers

Trial Profile

A phase I trial of OCR-002 for prevention of hepatic encephalopathy in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs Ornithine phenylacetate (Primary) ; Glycerol phenylbutyrate
  • Indications Hepatic encephalopathy
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Jan 2016 Complete plasma data published in an Ocera Therapeutics media release.
    • 16 Nov 2015 According to an Ocera Therapeutics media release, complete results from this trial will be submitted for presentation at an upcoming scientific conference.
    • 16 Nov 2015 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top